Top 5 Supermarket Companies To Own In Right Now: Novo Nordisk A/S (NVO)
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes care segment covers insulins, oral antidiabetic drugs, and other protein-related products and projects comprising glucagon and protein-related delivery systems, as well as GLP-1 analogue. The Biopharmaceuticals segment provides products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation therapy. Its products are marketed and distributed through subsidiaries, distributors, and independent agents in 180 countries. Novo Nordisk A/S has a collaboration agreement with Archimedes, Inc. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Advisors' Opinion:- [By Maxx Chatsko]
The company will now compete more readily with industry leaders Novozymes from Novo Nordisk (NYSE: NVO ) and Genencor from DuPont (NYSE: DD ) . However, the biggest effects could be felt at Codexis (NASDAQ: CDXS ) , which has also licensed the cutting-edge host organism from Dyadic. Will BASF's push into industrial enzymes, specifically using the C1 platform, vindicate Codexis or shove it out of the way?
- [By Bryan Murphy]
The advent of stem cell biotechnology has put several diseases and ailments in the crosshairs... cancer, multiple sclerosis, arthritis, and even brain injuries, just to name a few. There are no limits to what cell-based therapies could do, however, with the right ingenuity and know-how. That's how a small cap, off-the-radar company called BioRestorative Therapies, Inc. (OTCBB:BRTX) may be about to make life much more difficult for bigger diabetes players like Johnson & Johnson (NYSE:JNJ) and Novo Nordisk A/S (NYSE:NVO).! p>
- [By Max Macaluso, Ph.D. and David Williamson]
In this video, health-care analysts David Williamson and Max Macaluso discuss how two Big Pharma companies --Novo Nordisk (NYSE: NVO ) and AstraZeneca (NYSE: AZN ) -- might become the next major players in the obesity space. (NYSE: AZN )
- [By Charles Carlson, CEO and Portfolio Manager, Horizon Investment Services]
For investors looking for growth but also income, I especially like three health-care related stocksFresenius Medical (FMS), Novo Nordisk (NVO), and Smith & Nephew (SNN).
source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-5-supermarket-companies-to-own-in-right-now-2.html
No comments:
Post a Comment